Effects of COVID‐19 on Parkinson's Disease Clinical Features: A Community‐Based Case‐Control Study

The impact of coronavirus disease 2019 (COVID‐19) on clinical features of Parkinson's disease (PD) has been poorly characterized so far. Of 141 PD patients resident in Lombardy, we found 12 COVID‐19 cases (8.5%), whose mean age and disease duration (65.5 and 6.3 years, respectively) were simila...

Full description

Saved in:
Bibliographic Details
Published inMovement disorders Vol. 35; no. 8; pp. 1287 - 1292
Main Authors Cilia, Roberto, Bonvegna, Salvatore, Straccia, Giulia, Andreasi, Nico Golfrè, Elia, Antonio E., Romito, Luigi M., Devigili, Grazia, Cereda, Emanuele, Eleopra, Roberto
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 01.08.2020
Wiley Subscription Services, Inc
Subjects
Betacoronavirus - pathogenicity
Brief Report
Case-Control Studies
Clinical deterioration
Cognition - physiology
Cognition Disorders - virology
Cognitive ability
Coronavirus Infections - complications
Coronavirus Infections - virology
Coronaviruses
COVID-19
Depression - psychology
Depression - virology
Dopamine receptors
Humans
Movement disorders
Neurodegenerative diseases
Pandemics
Parkinson Disease - complications
Parkinson Disease - physiopathology
Parkinson Disease - virology
Parkinson's disease
Pharmacokinetics
Pneumonia, Viral - complications
Pneumonia, Viral - virology
SARS-CoV-2
Special Series
Online AccessGet full text

Cover

More Information
Summary:The impact of coronavirus disease 2019 (COVID‐19) on clinical features of Parkinson's disease (PD) has been poorly characterized so far. Of 141 PD patients resident in Lombardy, we found 12 COVID‐19 cases (8.5%), whose mean age and disease duration (65.5 and 6.3 years, respectively) were similar to controls. Changes in clinical features in the period January 2020 to April 2020 were compared with those of 36 PD controls matched for sex, age, and disease duration using the clinical impression of severity index for PD, the Movement Disorders Society Unified PD Rating Scale Parts II and IV, and the nonmotor symptoms scale. Motor and nonmotor symptoms significantly worsened in the COVID‐19 group, requiring therapy adjustment in one third of cases. Clinical deterioration was explained by both infection‐related mechanisms and impaired pharmacokinetics of dopaminergic therapy. Urinary issues and fatigue were the most prominent nonmotor issues. Cognitive functions were marginally involved, whereas none experienced autonomic failure. © 2020 International Parkinson and Movement Disorder Society
Bibliography:Salvatore Bonvegna, Giulia Straccia, and Nico Golfrè Andreasi contributed equally to this article.
Nothing to report.
Relevant conflicts of interests/financial disclosures
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
Relevant conflicts of interests/financial disclosures: Nothing to report.
ISSN:0885-3185
1531-8257
1531-8257
DOI:10.1002/mds.28170